• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

    6/17/25 7:30:35 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    8-K
    DYNAVAX TECHNOLOGIES CORP false 0001029142 --12-31 0001029142 2025-06-11 2025-06-11
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 11, 2025

     

     

    Dynavax Technologies Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-34207   33-0728374

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2100 Powell Street, Suite 720  
    Emeryville, California   94608
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (510) 848-5100

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 par value   DVAX   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 3.03.

    Material Modification to Rights of Security Holders.

    The information set forth in Item 5.03 below is incorporated by reference herein.

     

    Item 5.03.

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    Amendments to Certificate of Incorporation

    As described in Item 5.07 below, at the 2025 Annual Meeting of Stockholders of Dynavax Technologies Corporation (the “Company”) held on June 11, 2025, pursuant to notice duly given (the “Annual Meeting”), the stockholders of the Company approved the amendment and restatement of the Company’s Restated Certificate of Incorporation, in the form of the Restated Certificate of Incorporation (the “Restated Certificate”) included as an appendix to the definitive proxy statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 17, 2025 (the “Proxy Statement”), to declassify the board of directors of the Company (the “Board”) on a phased basis over a three-year period starting in 2026, thereby providing for the annual election of all directors beginning at the 2028 Annual Meeting of Stockholders of the Company, and to make certain conforming and technical changes to the Company’s certificate of incorporation.

    On June 16, 2025, the Company filed the Restated Certificate with the Secretary of the State of Delaware.

    Amendments to Bylaws

    Concurrent with the filing of the Restated Certificate, Section 5(d) and Section 17 of the Company’s Amended and Restated Bylaws were amended to conform to the changes reflected in the Restated Certificate, to read as follows:

    Section 5(d):

    “(d) Notwithstanding anything in Section 5(b)(iii) to the contrary, in the event that, prior to the corporation’s annual meeting of stockholders held in calendar year 2027, the number of directors in an Expiring Class is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made, of the vacancy in such class, made by the corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with Section 5(b)(iii), a stockholder’s notice required by this Section 5 and which complies with the requirements in Section 5(b)(i), other than the timing requirements in Section 5(b)(iii), shall also be considered timely, but only with respect to nominees for any new positions in such Expiring Class created by such increase, if it shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation. For purposes of this section, an “Expiring Class” shall mean a class of directors whose term shall expire at the next annual meeting of stockholders.”

    “Section 17. Term of Office. The term of office of each director shall be as provided in the Certificate of Incorporation.”

    A copy of the Restated Certificate is attached as Exhibit 3.1 and a copy of the Company’s Amended and Restated Bylaws, as amended, is attached as Exhibit 3.2 to this Current Report on Form 8-K, both of which are incorporated into this Item 5.03 by reference.

     

    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    As of April 14, 2025, the record date for the Annual Meeting, a total of 122,411,685 shares of Common Stock were outstanding and entitled to vote. Based on a final certified report of voting results from First Coast Results, Inc. (the “Inspector of Election”), there were 96,738,122 shares present in person or by proxy, constituting a quorum, at the Annual Meeting. Set forth below are the matters acted upon by the stockholders, and the certified final voting results with respect to each matter as provided by the Inspector of Election. The proposals are described in detail in the Proxy Statement.


    Proposal 1. Election of Directors

    The stockholders elected Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun, as Class I directors of the Company to hold office until the 2028 annual meeting of stockholders or until their respective successors are duly elected and qualified. The voting for each director was as follows:

    Company’s Nominees

     

    Nominee

       Votes Cast For    Votes Withheld    Broker Non-Votes

    Brent MacGregor

       59,298,357    37,273,503    N/A

    Scott Myers

       59,182,029    37,389,832    N/A

    Lauren Silvernail

       63,055,095    33,516,764    N/A

    Elaine Sun

       61,648,933    34,922,928    N/A

    Deep Track Capital LP’s (“Deep Track”) Nominees

     

    Nominee

       Votes Cast For    Votes Withheld    Broker Non-Votes

    Brett Erkman

       36,043,570    60,527,881    N/A

    Jeffrey Farrow

       32,761,981    63,809,470    N/A

    Michael Mullette

       32,682,611    63,888,840    N/A

    Donald Santel

       35,909,644    60,661,684    N/A

    Proposal 2. Advisory Vote on Executive Compensation

    The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were as follows:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    88,358,585   7,283,834   938,871   156,832

    Proposal 3. Ratification of Selection of Independent Registered Public Accounting Firm

    The stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes were as follows:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    90,492,937   5,492,709   752,476   0


    Proposal 4. Amendment and Restatement of the Company’s Restated Certificate of Incorporation to Declassify the Board on a Phased Basis

    The stockholders approved the proposal to amend and restate the Company’s Restated Certificate of Incorporation to provide for the phased declassification of the Board and to implement certain other changes. The votes were as follows:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    94,196,115   1,575,494   809,682   156,831

    Proposal 5. Stockholder Proposal to Amend the Company’s Amended and Restated Bylaws to Repeal Any Amendments Without Stockholder Approval Subsequent to November 6, 2018

    The stockholders did not approve the stockholder proposal to repeal each provision of, or amendment to, the Company’s Amended and Restated Bylaws adopted by the Board without stockholder approval subsequent to November 6, 2018. The votes were as follows:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    36,117,037   59,801,395   662,858   156,832

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number

      

    Description

    3.1

       Restated Certificate of Incorporation

    3.2

       Amended and Restated Bylaws, as Amended

    104

       Cover Page Interactive Data (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        Dynavax Technologies Corporation
    Date: June 17, 2025   By:  

    /s/ Ryan Spencer

       

    RYAN SPENCER

    Chief Executive Officer

    Get the next $DVAX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

      EMERYVILLE, Calif., June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted to elect all four of its director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – to the Company's Board of Directors. Dynavax issued the following statement:

      6/11/25 11:01:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

      Deep Track's Nominees Are Prepared to Collectively Enter the Boardroom with Open-Minded Perspectives, Constructive Approach and Sole Focus on Creating Value for All Shareholders Believes that Without Meaningful Board Change "Valid and Critical Questions Regarding Dynavax's Strategic Direction, Capital Allocation, and Board Responsiveness" Will Remain Unanswered Details Urgent Need to Address Company's Consistent Failure to Achieve Stated Targets and Reverse Heplisav Market Share Stagnation Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"),

      6/9/25 8:30:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

      Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., June 9, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote "FOR" all four of Dynavax's highly qualified directors standing for e

      6/9/25 7:30:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:55:43 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kisner Daniel L was granted 5,758 shares, increasing direct ownership by 33% to 23,329 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:53:29 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Myers Scott Dunseth was granted 5,758 shares, increasing direct ownership by 23% to 31,204 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      6/13/25 5:51:37 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    SEC Filings

    See more
    • Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

      8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/17/25 7:30:35 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/9/25 7:44:29 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      6/6/25 6:04:24 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dynavax downgraded by Goldman with a new price target

      Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

      2/11/25 7:05:05 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Dynavax with a new price target

      Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

      2/1/24 6:20:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Dynavax with a new price target

      JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

      9/27/22 7:39:04 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Financials

    Live finance-specific insights

    See more
    • Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

      Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.

      5/6/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav

      4/22/25 4:00:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

      HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.

      2/20/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Deep Track Capital Comments on ISS Recommendation

      Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

      5/23/25 6:12:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

      ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

      5/23/25 1:44:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • /C O R R E C T I O N -- Dynavax Technologies/

      In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum, issued 07-May-2025 by Dynavax Technologies over PR Newswire, we are advised by the company that the second paragraph, second sentence of the stockholder letter should read "Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology Select Industry Index's return of -7%[2]." rather than "Dynavax has generated approximately $1 billion of stockholder value, returning over 104% versus the S&P Biotechnology Select Industry Index's return of only 14%[2]." as originally issued inadvertently. The complete, corre

      5/7/25 4:45:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Dynavax Technologies Corporation

      SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      11/14/24 12:18:08 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

      SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/24/24 4:06:57 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

      SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/16/24 9:37:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care